Biogen (BIIB) Tops Q1 EPS by 6c; cuts guidance

Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.02, $0.06 better than the analyst estimate of $2.96. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.23 billion.

GUIDANCE:

Biogen sees FY2025 EPS of $14.50-$15.50, versus the consensus of $15.20.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• BofA Securities Downgrades StubHub Holdings (STUB) to Underperform
• Axis Capital Limited Downgrades National Aluminium (NACL:IN) to Sell (4)